
FDA Grants Fast Track Designation for Acute Radiation Syndrome Countermeasure
Aeolus Pharmaceuticals has been granted Fast Track designation for AEOL 10150 for the prevention of fatal respiratory failure among patients at risk for radiation pneumonitis following a radiological/nuclear incident. AEOL 10150 protects tissue [Read more]